Hyperhomocysteinemia
Hyperhomocysteinemia has been studied in 3 papers since 2019: 2 observational studies in people, 1 review; 1 in the past year. The newest paper, Jul 30, 2026: “Hyperhomocysteinemia and the risk of silent brain infarcts: systematic review and meta-analysis”.
3 papers study it6 findingsUpdated
See all 3 papers on hyperhomocysteinemia
At a glance
The findings reach people, from one lab or study. 3 independent labs in 3 countries.
“HWC/HHcy(+) group having the highest risk (OR = 13.52; 95% CI = 8.61-14.55)”
None of its findings points the other way.
- 3 independent labs in 3 countries
- Funders: National Natural Science Foundation of China and others
- Humans2
What did studies of hyperhomocysteinemia find?
2Studies of hyperhomocysteinemia measured 2 outcomes: MMSE and intrinsic capacity Z-score.
MMSE
no changein humans1
1 study
MMSE
no changein humans1
Hyperhomocysteinemia showed no clear effect on MMSE in humans (mean difference -1.55, 95% CI -3.60-0.50).
“MMSE scores were numerically lower in patients with hyperhomocysteinemia but did not differ significantly from controls (mean difference -1.55; 95% CI -3.60-0.50; P = 0.14).”
Review
Hyperhomocysteinemia and the risk of silent brain infarcts: systematic review and meta-analysis
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
Intrinsic capacity Z-score
downin humans1
1 study
Intrinsic capacity Z-score
downin humans1
Hyperhomocysteinemia is linked with lower intrinsic capacity Z-score in humans.
“Participants with HHcy also presented IC Z-score decreases over time.”
Humans5 yearsn = 1,516
Experimental gerontology
What is hyperhomocysteinemia linked with?
4Studies link hyperhomocysteinemia with 4 measures, among them silent brain infarct, mortality and cardiovascular disease mortality.
Silent brain infarct
upin humans1OR 1.84
1 study
Silent brain infarct
upin humans1OR 1.84
Hyperhomocysteinemia raises the risk of silent brain infarct in humans (OR 1.84, 95% CI 1.09-3.11).
“The rate of silent brain infarcts was 23.4% (253/1087) in patients with hyperhomocysteinemia versus 22.8% (284/1244) in controls (OR 1.84; 95% CI 1.09-3.11; P = 0.02).”
Reviewbrainn = 2,331
Hyperhomocysteinemia and the risk of silent brain infarcts: systematic review and meta-analysis
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
Mortality
upin humans1HR 1.23
1 study
Mortality
upin humans1HR 1.23
Hyperhomocysteinemia is linked with a higher risk of mortality in humans with abdominal obesity [HWC/HHcy(+)] vs NWC/HHcy(-) (HR = 1.23; 95% CI = 1.04-2.18).
“all-cause mortality (HR = 1.23; 95% CI = 1.04-2.18) of HWC/HHcy(+) group increased considerably after adjustment for major MetS and CVD risk factors”
Humanswith abdominal obesity [HWC/HHcy(+)] vs NWC/HHcy(-)7-year follow-upn = 3,675
Frontiers in cardiovascular medicine
Cardiovascular disease mortality
upin humans1HR 1.75
1 study
Cardiovascular disease mortality
upin humans1HR 1.75
Hyperhomocysteinemia is linked with a higher risk of cardiovascular disease mortality in humans with abdominal obesity [HWC/HHcy(+)] vs NWC/HHcy(-) (HR = 1.75; 95% CI = 1.02-3.03).
“risk of 7-year follow-up CVD mortality (HR = 1.75; 95% CI = 1.02-3.03) and all-cause mortality (HR = 1.23; 95% CI = 1.04-2.18) of HWC/HHcy(+) group increased considerably”
Humanswith abdominal obesity [HWC/HHcy(+)] vs NWC/HHcy(-)7-year follow-upn = 3,675
Frontiers in cardiovascular medicine
Metabolic syndrome
upin humans1OR 13.52
1 study
Metabolic syndrome
upin humans1OR 13.52
Hyperhomocysteinemia is linked with a higher risk of metabolic syndrome in humans with abdominal obesity [HWC/HHcy(+)] vs NWC/HHcy(-) (OR = 13.52; 95% CI = 8.61-14.55).
“HWC/HHcy(+) group having the highest risk (OR = 13.52; 95% CI = 8.61-14.55)”
Humanswith abdominal obesity [HWC/HHcy(+)] vs NWC/HHcy(-)7-yearn = 3,675
Frontiers in cardiovascular medicine